Takayasu's Arteritis Diagnosed in an Adolescent Patient with Crohn's Disease: Management of Biologicals.
Kazuya KishimotoYuji NozakiToshiharu SakuraiKoji KinoshitaMasanori FunauchiItaru MatsumuraPublished in: Life (Basel, Switzerland) (2021)
We report a 14-year-old man with Crohn's disease (CD) who developed right upper arm pain while being treated with the anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, infliximab. There were no symptoms suggestive of active CD, but the inflammatory response was high, and a contrast-enhanced CT showed the occlusion of the right brachial artery. We diagnosed the patient as having Takayasu's arteritis (TA) and started treatment with corticosteroids, then tapered off the steroids as the symptoms of TA resolved. Later, TA flared up, and his treatment was changed from infliximab to an anti-IL-6 receptor antibody, tocilizumab. The change to TCZ stabilized TA, but exacerbated CD. It is difficult to control both diseases at the same time, and the choice of biologics for treatment must be carefully considered.
Keyphrases
- contrast enhanced
- inflammatory response
- rheumatoid arthritis
- computed tomography
- magnetic resonance imaging
- monoclonal antibody
- magnetic resonance
- young adults
- chronic pain
- diffusion weighted
- combination therapy
- physical activity
- juvenile idiopathic arthritis
- lipopolysaccharide induced
- dual energy
- replacement therapy
- sleep quality
- ulcerative colitis
- disease activity